Desoximetasone

Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Sold as Topicort, Topicort LP. Every FDA application for this active ingredient: 6 branded and 34 generic.

As of Nov 15, 2026, FDA lists 40 applications for Desoximetasone (sold as Topicort, Topicort LP), first approved Feb 28, 1977, with 1 new use approved and 0 published complete response letters.

First approved: Feb 28, 1977
Applications: 40
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $2.8M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Desoximetasone	Part D	$2.8M	-20%	23,710

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

DESOXIMETASONE 0.05% CREAM: $1.51 per GMGeneric · +2% in a year
DESOXIMETASONE 0.05% GEL: $3.47 per GMGeneric · +3% in a year
DESOXIMETASONE 0.05% OINTMENT: $1.15 per GMGeneric · -28% in a year
DESOXIMETASONE 0.25% CREAM: $0.392 per GMGeneric · -1% in a year
DESOXIMETASONE 0.25% OINTMENT: $0.395 per GMGeneric · -17% in a year
DESOXIMETASONE 0.25% SPRAY: $0.696 per MLGeneric · -2% in a year

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Feb 28, 1977	TopicortNDA 17856 · New molecular entity	Taro	24	Discontinued
Mar 28, 1980	Topicort LPNDA 18309 · New dosage form	Taro	14	Discontinued
Mar 29, 1982	TopicortNDA 18586 · New dosage form	Taro	9	Discontinued
Oct 3, 1983	TopicortNDA 18763 · New dosage form	Taro	7	Discontinued
Jan 17, 1985	TopicortNDA 18594 · New dosage form	Taro	10	Marketed
Nov 29, 1990	TopicortANDA 73193	Taro	10	Marketed
Nov 30, 1990	TopicortANDA 73210	Taro	11	Marketed
Jun 7, 1996	TopicortANDA 74286	Taro	14	Discontinued
Apr 1, 1998	DesoximetasoneANDA 73440	Altana	0	Discontinued
Jul 14, 1998	TopicortANDA 74904	Taro	7	Marketed
Jul 1, 2003	DesoximetasoneANDA 76510	Padagis Israel	0	Marketed
Jan 9, 2006	DesoximetasoneANDA 77552	Padagis US	0	Discontinued
Jun 29, 2010	DesoximetasoneANDA 78369	Fougera Pharms	2	Marketed
Mar 10, 2011	DesoximetasoneANDA 90727	Epic Pharma LLC	0	Marketed
Sep 28, 2012	DesoximetasoneANDA 78657	Fougera Pharms	0	Marketed
Apr 11, 2013	TopicortNDA 204141 · New dosage form	Sun Pharma Canada	5	Marketed
Sep 20, 2013	DesoximetasoneANDA 202838	Glenmark Pharms Ltd	0	Discontinued
Apr 24, 2014	DesoximetasoneANDA 201005	Epic Pharma LLC	0	Marketed
Apr 20, 2015	DesoximetasoneANDA 77770	Padagis Israel	0	Marketed
Jun 12, 2015	DesoximetasoneANDA 203234	Sciegen Pharms	1	Marketed
Sep 4, 2015	DesoximetasoneANDA 205082	Actavis Mid Atlantic	0	Discontinued
Feb 25, 2016	DesoximetasoneANDA 208101	Encube	0	Discontinued
May 10, 2016	DesoximetasoneANDA 206792	Novel Labs Inc	0	Marketed
Aug 12, 2016	DesoximetasoneANDA 204675	Rising	0	Marketed
Nov 7, 2016	DesoximetasoneANDA 204965	Actavis Mid Atlantic	0	Marketed
Nov 30, 2016	DesoximetasoneANDA 204272	Rising	0	Marketed
Dec 1, 2016	DesoximetasoneANDA 208104	Lupin	0	Marketed
Dec 12, 2016	DesoximetasoneANDA 208044	Lupin	0	Marketed
Dec 23, 2016	DesoximetasoneANDA 206740	Cosette Pharms Nc	0	Discontinued
Jan 6, 2017	DesoximetasoneANDA 203787	Sciegen Pharms	1	Marketed
Jan 9, 2017	DesoximetasoneANDA 208164	Lupin	0	Marketed
Jan 11, 2017	DesoximetasoneANDA 208163	Lupin	0	Marketed
Jan 20, 2017	DesoximetasoneANDA 206441	Padagis Israel	1	Marketed
Sep 19, 2017	DesoximetasoneANDA 205206	Zydus Lifesciences	0	Marketed
Mar 16, 2018	DesoximetasoneANDA 208124	Lupin	0	Marketed
Jul 2, 2018	DesoximetasoneANDA 205594	Rising	0	Marketed
Sep 28, 2018	DesoximetasoneANDA 205620	Zydus Lifesciences	0	Marketed
Oct 23, 2018	DesoximetasoneANDA 209973	The J Molner	1	Marketed
Dec 21, 2018	DesoximetasoneANDA 210980	Rising	0	Marketed
Mar 4, 2020	DesoximetasoneANDA 209595	Cosette Pharms Nc	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA